微生物组疗法走向小分子。 - Suppr

Suppr

超能文献

Microbiome therapeutics go small molecule.

作者信息

Cully Megan

出版信息

Nat Rev Drug Discov. 2019 Jul;18(8):569-572. doi: 10.1038/d41573-019-00122-8.

DOI:10.1038/d41573-019-00122-8

PMID:31367062

Abstract

摘要

相似文献

Microbiome therapeutics go small molecule.

Nat Rev Drug Discov. 2019 Jul;18(8):569-572. doi: 10.1038/d41573-019-00122-8.

Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management.

Aliment Pharmacol Ther. 2018 Jan;47(1):26-42. doi: 10.1111/apt.14384. Epub 2017 Oct 16.

The microbiome and cancer for clinicians.

Crit Rev Oncol Hematol. 2019 Sep;141:1-12. doi: 10.1016/j.critrevonc.2019.06.004. Epub 2019 Jun 8.

Targeting friend and foe: Emerging therapeutics in the age of gut microbiome and disease.

J Microbiol. 2018 Mar;56(3):183-188. doi: 10.1007/s12275-018-8037-z. Epub 2018 Feb 28.

Xenobiotic and non-xenobiotic interventions in the microbiome therapeutics.

Curr Drug Metab. 2015;16(4):284-93. doi: 10.2174/138920021604150902180008.

Evaluation of genotoxicity testing of FDA approved large molecule therapeutics.

Regul Toxicol Pharmacol. 2014 Oct;70(1):87-97. doi: 10.1016/j.yrtph.2014.06.005. Epub 2014 Jun 13.

Microbiota-drug interactions: Impact on metabolism and efficacy of therapeutics.

Maturitas. 2018 Jun;112:53-63. doi: 10.1016/j.maturitas.2018.03.012. Epub 2018 Apr 5.

Impacts of the Human Gut Microbiome on Therapeutics.

Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:253-270. doi: 10.1146/annurev-pharmtox-042017-031849. Epub 2017 Oct 2.

Fecal Microbiota-based Therapeutics for Recurrent Clostridium difficile Infection, Ulcerative Colitis and Obesity.

EBioMedicine. 2016 Nov;13:37-45. doi: 10.1016/j.ebiom.2016.09.029. Epub 2016 Oct 1.

The microbiome as a human organ.

Clin Microbiol Infect. 2012 Jul;18 Suppl 4:2-4. doi: 10.1111/j.1469-0691.2012.03916.x.

引用本文的文献

Probing and manipulating the gut microbiome with chemistry and chemical tools.

Gut Microbiome (Camb). 2025 Apr 14;6:e6. doi: 10.1017/gmb.2025.4. eCollection 2025.

Human Gut Microbiome Researches Over the Last Decade: Current Challenges and Future Directions.

Phenomics. 2023 Oct 23;5(1):1-7. doi: 10.1007/s43657-023-00131-z. eCollection 2025 Feb.

Large-scale biosynthetic analysis of human microbiomes reveals diverse protective ribosomal peptides.

Nat Commun. 2025 Mar 28;16(1):3054. doi: 10.1038/s41467-025-58280-w.

Gut Microbial Targets in Inflammatory Bowel Disease: Current Position and Future Developments.

Biomedicines. 2025 Mar 14;13(3):716. doi: 10.3390/biomedicines13030716.

Gastrointestinal microbiota-directed nutritional and therapeutic interventions for inflammatory bowel disease: opportunities and challenges.

Gastroenterol Rep (Oxf). 2024 Apr 27;12:goae033. doi: 10.1093/gastro/goae033. eCollection 2024.

Exploring the diversity of blood microbiome during liver diseases: Unveiling Novel diagnostic and therapeutic Avenues.

Heliyon. 2023 Oct 30;9(11):e21662. doi: 10.1016/j.heliyon.2023.e21662. eCollection 2023 Nov.

Disease modification in inflammatory skin disorders: opportunities and challenges.

Nat Rev Drug Discov. 2023 Aug;22(8):662-680. doi: 10.1038/s41573-023-00735-0. Epub 2023 Jul 13.

Clinical trials targeting the gut-microbiome to effect ocular health: a systematic review.

Eye (Lond). 2023 Oct;37(14):2877-2885. doi: 10.1038/s41433-023-02462-7. Epub 2023 Mar 14.

Circulating microbiota and metabolites: Insights into cardiovascular diseases.

J Clin Lab Anal. 2022 Dec;36(12):e24779. doi: 10.1002/jcla.24779. Epub 2022 Nov 29.

Small molecule modulation of microbiota: a systems pharmacology perspective.

BMC Bioinformatics. 2022 Sep 29;23(Suppl 3):403. doi: 10.1186/s12859-022-04941-2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Microbiome therapeutics go small molecule.

Nat Rev Drug Discov. 2019 Jul;18(8):569-572. doi: 10.1038/d41573-019-00122-8.

Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management.

Aliment Pharmacol Ther. 2018 Jan;47(1):26-42. doi: 10.1111/apt.14384. Epub 2017 Oct 16.

The microbiome and cancer for clinicians.

Crit Rev Oncol Hematol. 2019 Sep;141:1-12. doi: 10.1016/j.critrevonc.2019.06.004. Epub 2019 Jun 8.

Targeting friend and foe: Emerging therapeutics in the age of gut microbiome and disease.

J Microbiol. 2018 Mar;56(3):183-188. doi: 10.1007/s12275-018-8037-z. Epub 2018 Feb 28.

Xenobiotic and non-xenobiotic interventions in the microbiome therapeutics.

Curr Drug Metab. 2015;16(4):284-93. doi: 10.2174/138920021604150902180008.

Evaluation of genotoxicity testing of FDA approved large molecule therapeutics.

Regul Toxicol Pharmacol. 2014 Oct;70(1):87-97. doi: 10.1016/j.yrtph.2014.06.005. Epub 2014 Jun 13.

Microbiota-drug interactions: Impact on metabolism and efficacy of therapeutics.

Maturitas. 2018 Jun;112:53-63. doi: 10.1016/j.maturitas.2018.03.012. Epub 2018 Apr 5.

Impacts of the Human Gut Microbiome on Therapeutics.

Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:253-270. doi: 10.1146/annurev-pharmtox-042017-031849. Epub 2017 Oct 2.

Fecal Microbiota-based Therapeutics for Recurrent Clostridium difficile Infection, Ulcerative Colitis and Obesity.

EBioMedicine. 2016 Nov;13:37-45. doi: 10.1016/j.ebiom.2016.09.029. Epub 2016 Oct 1.

The microbiome as a human organ.

Clin Microbiol Infect. 2012 Jul;18 Suppl 4:2-4. doi: 10.1111/j.1469-0691.2012.03916.x.

引用本文的文献

Probing and manipulating the gut microbiome with chemistry and chemical tools.

Gut Microbiome (Camb). 2025 Apr 14;6:e6. doi: 10.1017/gmb.2025.4. eCollection 2025.

Human Gut Microbiome Researches Over the Last Decade: Current Challenges and Future Directions.

Phenomics. 2023 Oct 23;5(1):1-7. doi: 10.1007/s43657-023-00131-z. eCollection 2025 Feb.

Large-scale biosynthetic analysis of human microbiomes reveals diverse protective ribosomal peptides.

Nat Commun. 2025 Mar 28;16(1):3054. doi: 10.1038/s41467-025-58280-w.

Gut Microbial Targets in Inflammatory Bowel Disease: Current Position and Future Developments.

Biomedicines. 2025 Mar 14;13(3):716. doi: 10.3390/biomedicines13030716.

Gastrointestinal microbiota-directed nutritional and therapeutic interventions for inflammatory bowel disease: opportunities and challenges.

Gastroenterol Rep (Oxf). 2024 Apr 27;12:goae033. doi: 10.1093/gastro/goae033. eCollection 2024.

Exploring the diversity of blood microbiome during liver diseases: Unveiling Novel diagnostic and therapeutic Avenues.

Heliyon. 2023 Oct 30;9(11):e21662. doi: 10.1016/j.heliyon.2023.e21662. eCollection 2023 Nov.

Disease modification in inflammatory skin disorders: opportunities and challenges.

Nat Rev Drug Discov. 2023 Aug;22(8):662-680. doi: 10.1038/s41573-023-00735-0. Epub 2023 Jul 13.

Clinical trials targeting the gut-microbiome to effect ocular health: a systematic review.

Eye (Lond). 2023 Oct;37(14):2877-2885. doi: 10.1038/s41433-023-02462-7. Epub 2023 Mar 14.

Circulating microbiota and metabolites: Insights into cardiovascular diseases.

J Clin Lab Anal. 2022 Dec;36(12):e24779. doi: 10.1002/jcla.24779. Epub 2022 Nov 29.

Small molecule modulation of microbiota: a systems pharmacology perspective.

BMC Bioinformatics. 2022 Sep 29;23(Suppl 3):403. doi: 10.1186/s12859-022-04941-2.